| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |




From the Department of Internal Medicine,*
Internal
Medicine and Medical Oncology, and the Department of
Biochemistry,
Biotechnology Research
Laboratories, Instituto di Ricovero e Cura a Carattere Scientifico
Policlinico S. Matteo, University of Pavia, Pavia; and the Hematology
Service,
Instituto di Ricovero e Cura a
Caraterre Scientifico Ospedale Policlinico, Milan, Italy
Primary amyloidosis is a fatal disorder characterized by
low numbers of clonal plasma cells in the bone marrow and the systemic
deposition of light chain fragments in the form of amyloid. The
molecular pathobiology of amyloidosis is primarily unknown.
Recently, a novel karyotypically undetectable
t(4;14)(p16.3;q32) translocation has been identified in
20% of
multiple myeloma patients. The translocation leads to the apparent
deregulation of two genes located on 4p16.3, the fibroblast
growth-factor receptor 3 (FGFR3), and the
putative transcription factor multiple myeloma SET
domain (MMSET), and to the generation of
IGH/MMSET hybrid transcripts. In this study, we
investigated the presence of the t(4;14) translocation in 42 AL
patients using a reverse transcriptase-polymerase chain reaction assay
for the detection of IGH/MMSET transcripts. Chimeric
transcripts were found in six patients (14%) and were consistent with
a 4p16.3 breakpoint involving intron 3 and juxtaposing
IGH regions to exon 4. In three of these cases,
hybrid transcripts juxtaposing IGH regions to exon 5
were also observed and were probably the result of an alternative
splicing skipping exon 4. Because all of the fusion transcripts (six of
six) excluded exon 3, the first translated MMSET
exon, only putative 5' truncated MMSET proteins could be
generated. In conclusion, our results demonstrate that the
t(4;14)(p16.3;q32) translocation is a recurrent genetic lesion in
primary amyloidosis.
This article has been cited by other articles:
![]() |
A. H. Bryce, R. P. Ketterling, M. A. Gertz, M. Lacy, R. A. Knudson, S. Zeldenrust, S. Kumar, S. Hayman, F. Buadi, R. A. Kyle, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis Haematologica, March 1, 2009; 94(3): 380 - 386. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Bochtler, U. Hegenbart, F. W. Cremer, C. Heiss, A. Benner, D. Hose, M. Moos, J. Bila, C. R. Bartram, A. D. Ho, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability Blood, May 1, 2008; 111(9): 4700 - 4705. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bink, E. Haralambieva, M. Kremer, G. Ott, C. Beham-Schmid, L. de Leval, S. C. Peh, H. R. Laeng, U. Jutting, P. Hutzler, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics Haematologica, April 1, 2008; 93(4): 623 - 626. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Keats, T. Reiman, C. A. Maxwell, B. J. Taylor, L. M. Larratt, M. J. Mant, A. R. Belch, and L. M. Pilarski In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression Blood, February 15, 2003; 101(4): 1520 - 1529. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |